Comparable stake leader
FMR LLC
SEC ownership of Roivant Sciences Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001635088.
Disclosed value leader
FMR LLC
Comparable rows
7/50
Latest evidence
10 Nov 2026
- Public ticker
- ROIV on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
7 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
10 Nov 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001635088
- Issuer location
- London
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Roivant Sciences Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
7/50
Latest evidence
10 Nov 2026
13D/G
13F
3/4/5
Lead comparable stake: 12%
43 rows are not safely comparable across share classes.
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 12%.
7 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
12%
BlackRock, Inc.
8.2%
MORGAN STANLEY
5.7%
QVT Financial LP
4.3%
Vivek Ramaswamy
3.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
|
12%
Reported 13D/G
· 30 Sep 2026
|
$2,960,058,360
85,575,552 shares
|
+$412,807,402 | 30 Sep 2026 |
| BlackRock, Inc. |
13D/G
|
8.2%
Reported 13D/G
· 30 Sep 2026
|
$2,168,059,142
59,285,183 shares
|
$0 | 30 Sep 2026 |
| MORGAN STANLEY |
13D/G
13F
Company
|
5.7%
Reported 13D/G
· 30 Jun 2026
|
$1,440,138,931
40,693,386 shares
|
-$310,740,090 | 30 Jun 2026 |
| QVT Financial LP |
3/4/5
13D/G
Director by Deputization
|
4.3%
Reported 13D/G
· 30 Jun 2025
|
$482,953,776
13,689,166 shares
|
-$147,382,307 | 26 Jun 2026 |
| Vivek Ramaswamy |
3/4/5
13D/G
10%+ Owner · Ramaswamy Vivek
|
3.6%
Reported 13D/G
· 31 Mar 2026
|
$1,012,161,165
69,161,839 shares
mixed-class rows
|
-$79,010,573 | 11 Dec 2025 |
| VIKING GLOBAL INVESTORS LP |
13D/G
3/4/5
10%+ Owner
|
3.4%
Reported 13D/G
· 30 Sep 2025
|
$356,989,793
23,594,831 shares
|
-$161,027,803 | 30 Sep 2025 |
| SB INVESTMENT ADVISERS (UK) LTD |
13D/G
SB Investment Advisers (UK) Limited
|
2.3%
Reported 13D/G
· 31 Dec 2025
|
$357,488,273
16,413,603 shares
|
-$520,575,193 | 31 Dec 2025 |
| Dexcel Pharma Technologies Ltd. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,064,491,735
102,849,443 shares
|
— | 10 Nov 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$888,462,585.
Buys
$0
Insiders: 0
Sells
$888,462,585
Insiders: 12
Net
-$888,462,585
Shares: -33,516,615
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 33,516,615
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 2,292,566 | $0 | $85,719,562 | -$85,719,562 |
| 3-6 | 0 | 6,385,416 | $0 | $218,702,049 | -$218,702,049 |
| 6-9 | 0 | 3,815,173 | $0 | $105,561,417 | -$105,561,417 |
| 9-12 | 0 | 21,023,460 | $0 | $478,479,557 | -$478,479,557 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 25 reporting-owner rows connected to Roivant Sciences Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
25
Largest Forms 3/4/5 holder
Dexcel Pharma Technologies Ltd.
Net 12M change
-$888.46M
Full value: -$888,462,583 · USD · 12-month changeLatest report
10 Nov 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Dexcel Pharma Technologies Ltd. | 10%+ Owner | $1,064,491,735 | Mixed | 10 Nov 2022 | ||
| Vivek Ramaswamy | 10%+ Owner | $1,012,161,165 | -$79,010,573 | -7.2% | Mixed | 11 Dec 2025 |
| Daniel Allen Gold | Director | $800,253,968 | -$147,382,307 | -16% | Mixed | 16 Sep 2026 |
| SVF Investments (UK) Ltd | 10%+ Owner | $755,877,753 | Mixed | 28 Sep 2023 | ||
| Sumitomo Chemical Co., Ltd. | 10%+ Owner | $737,448,709 | Mixed | 22 Jun 2023 | ||
| Mayukh Sukhatme | President & CIO, Director | $672,767,428 | -$109,133,247 | -14% | Median | 10 Nov 2026 |
| Matthew Gline | CEO, Director | $599,427,244 | -$46,173,010 | -7.2% | Median | 10 Nov 2026 |
| Keith S. Manchester | Director | $545,008,619 | -$154,472,307 | -22% | Mixed | 16 Sep 2026 |
| QVT Financial LP | Director by Deputization | $482,953,776 | -$147,382,307 | -23% | Filing P/S | 26 Jun 2026 |
| Frank Torti | President and Vant Chair | $450,065,161 | -$82,039,460 | -15% | Median | 10 Nov 2026 |
| Eric Venker | President & Immunovant CEO | $156,126,946 | -$94,970,152 | -38% | Mixed | 10 Nov 2026 |
| VIKING GLOBAL PERFORMANCE LLC | 10%+ Owner | $133,352,577 | Mixed | 22 Jun 2023 | ||
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $133,352,577 | Mixed | 22 Jun 2023 | ||
| Benjamin Zimmer | President, Roivant Health | $12,083,532 | Mixed | 01 Oct 2021 | ||
| Richard Pulik | Cfo | $9,301,506 | -$21,595,579 | -70% | Filing P/S | 10 Nov 2026 |
| Ilan Oren | Director | $4,552,599 | Median | 23 Oct 2026 | ||
| James C. Momtazee | Director | $4,105,531 | Median | 23 Oct 2026 | ||
| Jennifer Humes | Chief Accounting Officer | $3,766,168 | -$384,073 | -9.3% | Mixed | 20 Sep 2026 |
| Rakhi Kumar | Chief Accounting Officer | $1,739,920 | Mixed | 20 Feb 2025 | ||
| Meghan FitzGerald | Director | $1,456,723 | -$3,271,652 | -69% | Mixed | 16 Sep 2026 |
Recent insider transactions for Roivant Sciences Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Frank Torti | ROIV | Common Shares | Tax liability | -0.1% | -12,800 | 12,306,950 | 12 Nov 2026 | Direct | ||
| Frank Torti | ROIV | Common Shares | Other | -3.08% | -392,043 | 12,319,750 | 12 Nov 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Tax liability | -0.01% | -1,600 | 16,391,229 | 12 Nov 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Other | -0.3% | -48,988 | 16,392,829 | 12 Nov 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Tax liability | -0.01% | -1,737 | 18,396,703 | 12 Nov 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Other | -0.29% | -53,205 | 18,398,440 | 12 Nov 2026 | Direct | ||
| Frank Torti | ROIV | Common Shares | Other | -2.99% | -392,048 | 12,711,793 | 11 Nov 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Other | -0.3% | -48,988 | 16,441,817 | 11 Nov 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Other | -0.29% | -53,205 | 18,451,645 | 11 Nov 2026 | Direct | ||
| Richard Pulik | ROIV | Common Shares | Sale | -44.1% | -$7,323,272 | $41.85 | -175,000 | 222,046 | 11 Nov 2026 | Direct |
| Richard Pulik | ROIV | Common Shares | Options Exercise | 47.2% | 127,365 | 397,046 | 11 Nov 2026 | Direct | ||
| Richard Pulik | ROIV | Stock Option (Right to Buy) | Options Exercise | -20.7% | -127,365 | 487,635 | 11 Nov 2026 | Direct | ||
| Frank Torti | ROIV | Common Shares | Other | -2.9% | -392,052 | 13,103,841 | 10 Nov 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Other | -0.35% | -58,331 | 16,490,805 | 10 Nov 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Other | -0.32% | -59,034 | 18,504,850 | 10 Nov 2026 | Direct | ||
| Richard Pulik | ROIV | Common Shares | Sale | -31.7% | -$5,150,000 | $41.20 | -125,000 | 269,681 | 10 Nov 2026 | Direct |
| Richard Pulik | ROIV | Common Shares | Options Exercise | 46.4% | 125,000 | 394,681 | 10 Nov 2026 | Direct | ||
| Richard Pulik | ROIV | Stock Option (Right to Buy) | Options Exercise | -16.9% | -125,000 | 615,000 | 10 Nov 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Sale | -18.8% | -$7,617,074 | $40.53 | -187,943 | 811,211 | 10 Nov 2026 | Direct |
| Eric Venker | ROIV | Common Shares | Sale | -16.7% | -$7,262,000 | $36.31 | -200,000 | 999,154 | 03 Nov 2026 | Direct |
| Eric Venker | ROIV | Common Shares | Sale | -14.3% | -$7,318,000 | $36.59 | -200,000 | 1,199,154 | 28 Oct 2026 | Direct |
| Ilan Oren | ROIV | Common Shares | Award | 0.65% | 810 | 124,490 | 23 Oct 2026 | Direct | ||
| Melissa B. Epperly | ROIV | Common Shares | Tax liability | -0.75% | -116 | 15,351 | 23 Oct 2026 | Direct | ||
| Melissa B. Epperly | ROIV | Common Shares | Award | 3.43% | 513 | 15,467 | 23 Oct 2026 | Direct | ||
| James C. Momtazee | ROIV | Common Shares | Tax liability | -0.07% | -77 | 112,265 | 23 Oct 2026 | Direct | ||
| James C. Momtazee | ROIV | Common Shares | Award | 0.34% | 383 | 112,342 | 23 Oct 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Sale | -12.5% | -$7,022,668 | $35.11 | -200,000 | 1,399,154 | 20 Oct 2026 | Direct |
| Mayukh Sukhatme | ROIV | Common Shares | Tax liability | -0.11% | -19,976 | 18,563,884 | 16 Oct 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Tax liability | -0.21% | -34,638 | 16,549,136 | 16 Oct 2026 | Direct | ||
| Melissa B. Epperly | ROIV | Common Shares | Sale | -54.3% | -$640,861 | $36.10 | -17,750 | 14,954 | 01 Oct 2026 | Direct |
| Melissa B. Epperly | ROIV | Common Shares | Options Exercise | 118.7% | 17,750 | 32,704 | 01 Oct 2026 | Direct | ||
| Melissa B. Epperly | ROIV | Stock Option (Right to Buy) | Options Exercise | -10.5% | -17,750 | 151,416 | 01 Oct 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Tax liability | -0.46% | -76,171 | 16,583,774 | 30 Sep 2026 | Direct | ||
| Frank Torti | ROIV | Common Shares | Tax liability | 0.3% | 40,309 | 13,495,893 | 30 Sep 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Tax liability | -0.25% | -46,879 | 18,583,860 | 30 Sep 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Sale | -11.1% | -$7,324,000 | $36.62 | -200,000 | 1,599,154 | 30 Sep 2026 | Direct |
| Eric Venker | ROIV | Common Shares | Options Exercise | 12.5% | 200,000 | 1,799,154 | 30 Sep 2026 | Direct | ||
| Eric Venker | ROIV | Stock Option (Right to Buy) | Options Exercise | -5.2% | -200,000 | 3,644,834 | 30 Sep 2026 | Direct | ||
| Jennifer Humes | ROIV | Common Shares | Tax liability | -3.52% | -3,880 | 106,419 | 20 Sep 2026 | Direct | ||
| Richard Pulik | ROIV | Common Shares | Tax liability | -0.78% | -2,129 | 269,681 | 20 Sep 2026 | Direct | ||
| Keith S. Manchester | ROIV | Common Shares | Award | 0.29% | 5,054 | 1,753,457 | 16 Sep 2026 | Direct | ||
| Keith S. Manchester | ROIV | Stock Option (Right to Buy) | Award | 10,531 | 10,531 | 16 Sep 2026 | Direct | |||
| Daniel Allen Gold | ROIV | Common Shares | Award | 0.06% | 5,054 | 8,965,815 | 16 Sep 2026 | Direct | ||
| Daniel Allen Gold | ROIV | Stock Option (Right to Buy) | Award | 10,531 | 10,531 | 16 Sep 2026 | Direct | |||
| Ilan Oren | ROIV | Common Shares | Award | 4.26% | 5,054 | 123,680 | 16 Sep 2026 | Direct | ||
| Ilan Oren | ROIV | Stock Option (Right to Buy) | Award | 10,531 | 10,531 | 16 Sep 2026 | Direct | |||
| James C. Momtazee | ROIV | Common Shares | Award | 4.73% | 5,054 | 111,959 | 16 Sep 2026 | Direct | ||
| James C. Momtazee | ROIV | Stock Option (Right to Buy) | Award | 10,531 | 10,531 | 16 Sep 2026 | Direct | |||
| Meghan FitzGerald | ROIV | Common Shares | Award | 14% | 5,054 | 41,162 | 16 Sep 2026 | Direct | ||
| Meghan FitzGerald | ROIV | Stock Option (Right to Buy) | Award | 10,531 | 10,531 | 16 Sep 2026 | Direct |
* marks a reported price that did not pass the local price check.